The PE Ratio as of May 2025 (TTM) for Paradigm Biopharmaceuticals Limited (PBIGF) is -7.17

According to Paradigm Biopharmaceuticals Limited’s latest financial reports and current stock price. The company's current PE Ratio is -7.17. This represents a change of 141.49% compared to the average of -2.97 of the last 4 quarters.

Paradigm Biopharmaceuticals Limited (PBIGF) Historical PE Ratio (quarterly & annually)

How has PBIGF PE Ratio performed in the past?

The mean historical PE Ratio of Paradigm Biopharmaceuticals Limited over the last ten years is -12.46. The current -7.17 PE Ratio has changed 5.65% with respect to the historical average. Over the past ten years (40 quarters), PBIGF's PE Ratio was at its highest in in the December 2013 quarter at 0. The PE Ratio was at its lowest in in the December 2019 quarter at -27.77.

Paradigm Biopharmaceuticals Limited (PBIGF) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Paradigm Biopharmaceuticals Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Paradigm Biopharmaceuticals Limited (PBIGF) Average PE Ratio

How has PBIGF PE Ratio performed in the past?

The current PE Ratio of Paradigm Biopharmaceuticals Limited (PBIGF) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Paradigm Biopharmaceuticals Limited (PBIGF) PE Ratio vs. Peers

How is PBIGF’s PE Ratio compared to its peers?

Paradigm Biopharmaceuticals Limited’s PE Ratio is less than Sio Gene Therapies Inc. (-0.49), less than Magenta Therapeutics, Inc. (-0.02), less than TRACON Pharmaceuticals, Inc. (0), less than ARCA biopharma, Inc. (-0.02), greater than Alpine Immune Sciences, Inc. (-74.86), greater than AN2 Therapeutics, Inc. (-112.94), less than Ampio Pharmaceuticals, Inc. (-0.70), less than Monte Rosa Therapeutics, Inc. (-0.00), less than Candel Therapeutics, Inc. (49.67), less than Kintara Therapeutics, Inc. (-6.51), less than Fresh Tracks Therapeutics, Inc. (-0.04), less than SAB Biotherapeutics, Inc. (6.38), less than Theriva Biologics, Inc. (-0.54), less than Lisata Therapeutics, Inc. (-0.03), less than Cellectar Biosciences, Inc. (-1.01), less than Diffusion Pharmaceuticals Inc. (-0.47), less than Monopar Therapeutics Inc. (-3.94), less than Pulmatrix, Inc. (-0.66), less than Tenax Therapeutics, Inc. (-2.50), less than Scholar Rock Holding Corporation (-4.98), greater than XOMA Corporation (-11.61), greater than UroGen Pharma Ltd. (-112.36), less than Lumos Pharma, Inc. (-3.29), less than null (-1.04),

Build a custom stock screener for Paradigm Biopharmaceuticals Limited (PBIGF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Paradigm Biopharmaceuticals Limited using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Paradigm Biopharmaceuticals Limited (PBIGF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Paradigm Biopharmaceuticals Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.